Le Lézard
Classified in: Health, Business
Subjects: NPT, SVY, LIC, DIS

The Christopher & Dana Reeve Foundation and Kessler Foundation Announce Novel Pilot Study to Improve Bladder Health in Individuals with Spinal Cord Injury


Clinical trial will utilize Butterfly iQtm to address one of the most common and challenging medical conditions related to spinal cord injury

SHORT HILLS, N.J., May 6, 2024 /PRNewswire/ -- The Christopher & Dana Reeve Foundation and Kessler Foundation announced today a pilot study to revolutionize bladder management for individuals with spinal cord injuries (SCI). The study introduces the Butterfly iQtm, a cutting-edge, portable ultrasound device that enables those living with SCI to monitor their bladder volume at home, potentially mitigating the risk of urinary tract infections (UTIs), which often result from improper bladder management.

"After a spinal cord injury, disrupted communication between the bladder muscles and the brain can lead to UTIs and long-term health complications," says Marco Baptista, Ph.D., Chief Scientific Officer, Christopher & Dana Reeve Foundation. "Our goal at the Reeve Foundation is not only to understand these challenges but to pioneer innovative solutions that may enhance the quality of life for those living with SCIs."

The study is being funded through a $56,559 grant from the Reeve Foundation and underscores the nonprofit's commitment to addressing secondary conditions that severely impact quality of life.

The study will recruit ten participants from the Kessler Institute for Rehabilitation's Urology and SCI Outpatient programs. The primary study objective is to determine if the use of the bladder ultrasound improves the quality of life in relation to bladder management for people with SCI who routinely perform intermittent catheterization.

This exciting pilot study offers new hope for individuals facing neurogenic bladder after an SCI.

Based upon the results, consideration for a larger clinical trial will be undertaken to see if this improves the frequency of medical complications, including leakage between catheterizations and UTIs.

Steven Kirshblum, MD, Chief Medical Officer for Kessler Foundation and Kessler Institute for Rehabilitation remarked, "This presents an excellent chance to explore cutting-edge technology directly accessible to patients/caregivers, potentially elevating their quality of life. Moreover, it could enhance medical care and help prevent bladder-related complications."

About the Christopher & Dana Reeve Foundation 

The Christopher & Dana Reeve Foundation?is dedicated to curing spinal cord injury by funding innovative research and improving the quality of life for individuals and families impacted by paralysis. Additionally, through a cooperative agreement with the Administration for Community Living, the Reeve Foundation's?National Paralysis Resource Center?(NPRC) promotes the health, well-being, and independence of people living with paralysis, providing comprehensive information, resources, and referral services assisting over 125,000 individuals and families since its launch in 2002. The Reeve Foundation is committed to elevating our community's voices and needs to achieve greater representation and independence. 

We meet all 20 of the Better Business Bureau's standards for charity accountability and hold the BBB's Charity Seal. For more information, please visit?ChristopherReeve.org?or call 800-225-0292. 

About Kessler Foundation

Kessler Foundation, a major nonprofit organization in the field of disability, is a global leader in rehabilitation research. Our scientists seek to improve cognition, mobility, and long-term outcomes, including employment, for adults and children with neurological and developmental disabilities of the brain and spinal cord including traumatic brain injury, spinal cord injury, stroke, multiple sclerosis, and autism. Kessler Foundation also leads the nation in funding innovative programs that expand opportunities for employment for people with disabilities.

SOURCE Christopher & Dana Reeve Foundation


These press releases may also interest you

at 03:15
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

at 02:05
PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces the opening of its proposed $100 million tender offer (the "Tender...



News published on and distributed by: